1. In Vivo

From PhD To Unicorn: Mammoth CEO On Pharma Deals and Squishy Biology

Mammoth BioSciences is co-founded by CRISPR pioneer Jennifer Doudna

 
• By Jo Shorthouse

Trevor Martin talked to In Vivo about the importance of sharing a strategic vision with partners, the company’s superpower, and how a PhD is the best prep for a startup.

Unicorn Mammoth Continues To Sign Big Pharma Partnerships

In April, Regeneron Pharmaceuticals, Inc. and Mammoth Biosciences, Inc. announced a collaboration to advance in vivo CRISPR-based gene editing therapies. This partnership was put in place to develop and commercialize innovative treatments targeting multiple tissues and cell types.

Mammoth Biosciences develops novel clustered regularly interspaced short palindromic repeats (CRISPR) systems

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

More from Leadership

Rising Leaders 2025: Rob Barrow On Leading MindMed’s Psychedelic Renaissance

 
• By Jo Shorthouse

Rob Barrow's unconventional journey from finance to leading MindMed highlights his innovative approach to psychedelic medicine, aiming to transform mental health treatment with groundbreaking therapies.

UCB’s Alistair Henry On How AI Is Reshaping Biopharma Talent

 
• By Jo Shorthouse

Artificial intelligence is shaping many facets of the drug development and commercialization continuum. The need for computational skills within drug R&D is also changing what companies are looking for in young talent that is capable of both bridge biological expertise with computational literacy.

Rising Leaders 2025: Stefan König On The Joy Of Watching Talent Grow

 
• By Urtė Fultinavičiūtė

While there might be different recipes for success in leadership, continuous learning and wide-ranging experiences have made Stefan König ready to lead Merz Therapeutics as CEO.